Jubilant DraxImage Inc.

Juniper Biosciences Secures $40 Million Seed Funding to Advance Radiopharmaceutical Pipeline

- Juniper Biosciences closed an oversubscribed and upsized $40 million seed financing round co-led by NovaCapital and high-net-worth investors to fund its radiopharmaceutical development programs. - The company is led by experienced executives from Evergreen Theragnostics and Jubilant Radiopharma, bringing deep expertise in global radiopharmaceutical development and manufacturing. - Juniper's confidential pipeline contains several assets in various stages of development focused on radiopharmaceutical imaging and therapy applications. - The funding will support advancement of the company's patient-centric product pipeline aimed at driving meaningful progress in radiopharmaceutical treatments.